Levocetirizine

Cat. No.:	HY-B0814
CAS No.:	130018-77-8
Molecular Formula:	$C_{21}H_{25}ClN_2O_3$
Molecular Weight:	388.89
Target:	Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the COA.



BIOLOGICAL ACTIVITY

Description

Levocetirizine ((R)-Cetirizine) is a third-generation **peripheral H1-receptor** antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the **histamine H1-receptor** than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria[1].

In Vivo

Levocetirizine (0.4 mg/kg; oral administration; male Sprague-Dawley rats) treatment shows that the C_{max}, AUC_{0-t}, $AUC_{0-\infty}$ and $t_{1/2}$ are 0.34 μg/mL, 3.26 μg h/mL, 3.67 μg h/mL and 2.34 hours, respectively in Sprague-Dawley rats[1].

Animal Model:	30 male Sprague-Dawley rats (8 weeks old; 200-250 g)[1]
Dosage:	0.4 mg/kg
Administration:	Oral administration (Pharmacokinetic Analysis)
Result:	The C_{max}, AUC_{0-t}, $AUC_{0-\infty}$ and $t_{1/2}$ were 0.34 μg/mL, 3.26 μg h/mL, 3.67 μg h/mL and 2.34 hours, respectively.

REFERENCES

[1]. Lohar P, et al. Simultaneous bioanalysis and pharmacokinetic interaction study of acebrophylline, levocetirizine and pranlukast in Sprague-Dawley rats. Biomed Chromatogr. 2019 Dec;33(12):e4672.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA